N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: A LIFE study

Journal of Hypertension

Volumn 22, Issue 8, 2004, Pages 1597-1604

  Olsen, Michael H ^a   Wachtell, Kristian ^a   Tuxen, Christian ^b   Fossum, Eigil ^c   Bang, Lia E ^a   Hall, Christian ^d   Ibsen, Hans ^a   Rokkedal, Jens ^a   Devereux, Richard B ^e   Hildebrandt, Per ^b  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b FREDERIKSBERG HOSPITAL   (Denmark)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d Rigshospitalet   (Norway)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cardiovascular risk; Hypertension; Left ventricular hypertrophy; Natriuretic peptides; Nt proANP; Nt proBNP

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; N TERMINAL PRO ATRIAL NATRIURETIC PEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOASSAY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DOPPLER ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HAZARD ASSESSMENT; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; IMMUNOASSAY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; REGRESSION ANALYSIS; STROKE;

EID: 3843098192     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000125451.28861.2a     Document Type: Article

References (28)

1. Ballermann BJ, Brenner BM. George E. Brown memorial lecture. Role of atrial peptides in body fluid homeostasis. Circ Res 1986; 58:619-630.
2. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988; 332:78-81.
3. Saito Y, Nakao K, Itoh H, Yamada T, Mukoyama M, Arai H, et al. Brain natriuretic peptide is a novel cardiac hormone. Biochem Biophys Res Commun 1989; 158:360-368.
4. Yoshimura M, Yasue H, Okumura K, Ogawa H, Jougasaki M, Mukoyama M, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993; 87:464-469.
5. Raizada V, Thakore K, Luo W, McGuire PG. Cardiac chamber-specific alterations of ANP and BNP expression with advancing age and with systemic hypertension. Mol Cell Biochem 2001; 216:137-140.
6. Sundsfjord JA, Thibault G, Larochelle P, Cantin M. Identification and plasma concentrations of the N-terminal fragment of proatrial natriuretic factor in man. J Clin Endocrinol Metab 1988; 66:605-610.
7. Qi W, Mathisen P, Kjekshus J, Simonsen S, Bjornerheim R, Endresen K, Hall C. Natriuretic peptides in patients with aortic stenosis. Am Heart J 2001; 142:725-732.
8. Hall C, Rouleau JL, Moye L, de Champlain J, Bichet D, Klein M, et al. N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. Circulation 1994; 89:1934-1942.
9. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, von Scheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001; 38:1934-1941.
10. Maeda K, Tsutamoto T, Wada A, Mabuchi N, Hayashi M, Tsutsui T, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000; 36:1587-1593.
11. Wallen T, Landahl S, Hedner T, Nakao K, Saito Y. Brain natriuretic peptide predicts mortality in the elderly. Heart 1997; 77:264-267.
12. McDonagh TA, Cunningham AD, Morrison CE, McMurray JJ, Ford I, Morton JJ, Dargie HJ. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 2001; 86:21-26.
13. Devereux RB, Okin PM, Roman MJ. Left ventricular hypertrophy as a surrogate end-point in hypertension. Clin Exp Hypertens 1999; 21:583-593.
14. Kohno M, Horio T, Yokokawa K, Murakawa K, Yasunari K, Akioka K, et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med 1992; 92:29-34.
15. Yamamoto K, Burnett JCJ, Jougasaki M, Nishimura RA, Bailey KR, Saito Y, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996; 28:988-994.
16. Dahlof B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, de Faire U, et al. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Hypertension 1998; 32:989-997.
17. Wachteil K, Bella JN, Liebson PR, Gerdts E, Dahlof B, Aalto T, et al. Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population: the LIFE study. Hypertension 2000; 35:6-12.
18. Devereux RB, Bella J, Boman K, Gerdts E, Nieminen MS, Rokkedal J, et al. Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. Blood Press 2001; 10:74-82.
19. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58:1072-1083.
20. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2:358-367.
21. Palmieri V, Dahlof B, DeQuattro V, Sharpe N, Bella JN, de Simone G, et al. Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement. J Am Coll Cardiol 1999; 34:1625-1632.
22. Wachtell K, Rokkedal J, Bella JN, Aalto T, Dahlof B, Smith G, et al. Effect of electrocardiographic left ventricular hypertrophy on left ventricular systolic function in systemic hypertension (The LIFE Study). Losartan Intervention For Endpoint. Am J Cardiol 2001; 87:54-60.
23. de Simone G, Devereux RB, Roman MJ, Ganau A, Saba PS, Alderman MH, Laragh JH. Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension. J Am Coll Cardiol 1994; 23:1444-1451.
24. Omland T, de Lemos JA, Morrow DA, Antman EM, Cannon CP, Hall C, Braunwald E. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol 2002; 89:463-465.
25. Wang TJ, Larson MG, Levy D, Leip EP, Benjamin EJ, Wilson PW, et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002; 90:254-258.
26. Lee SC, Stevens TL, Sandberg SM, Heublein DM, Nelson SM, Jougasaki M, et al. The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J Card Fail 2002; 8:149-154.
27. Yoshimura M, Mizuno Y, Nakayama M, Sakamoto T, Sugiyama S, Kawano H, et al. B-type natriuretic peptide as a marker of the effects of enalapril in patients with heart failure. Am J Med 2002; 112:716-720.
28. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355:1126-1130.